Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Satellos Bioscience ( (TSE:MSCL) ).
Satellos Bioscience has reported significant progress in its clinical trials for SAT-3247, a potential oral therapy for DMD. The company completed a Phase 1a trial showing safety and promising pharmacokinetic results, and has initiated a Phase 1b trial with results expected in Q2 2025. Financially, Satellos strengthened its position with a $40 million equity offering, increasing its cash reserves to $69.9 million, which is expected to support operations through 2026 and advance SAT-3247 through Phase 2 trials.
More about Satellos Bioscience
Satellos Bioscience Inc. is a clinical-stage biotechnology company focused on developing life-improving medicines for degenerative muscle diseases. The company is advancing its primary product, SAT-3247, which is aimed at treating Duchenne muscular dystrophy (DMD).
YTD Price Performance: -12.70%
Average Trading Volume: 137,390
Technical Sentiment Signal: Hold
Current Market Cap: $83.8M
See more data about MSCL stock on TipRanks’ Stock Analysis page.